SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu Crypto is experiencing a surge in conversation fueled by its exceptionally active and dedicated community, which is relentlessly building a "permissionless brand" with numerous real-world products like Kendu Spice and Kendu Energy. This collective effort, marked by strong IRL initiatives and a long-term vision, sets KENDU apart, leading to a prevalent bullish sentiment across the crypto space.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending amid intense debate, as investors grapple with its persistent stock decline despite new strategic AI partnerships and potential tailwinds from discussions around credit card interest rate caps. While many criticize management and predict further drops given recent analyst downgrades, a significant portion of the community views PYPL as profoundly undervalued, actively accumulating shares and anticipating a strong rebound.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant buzz following robust preliminary financial updates, which highlighted record contract value and strong revenue expansion. The community is engaged in discussions surrounding its expanding partnerships with major pharmaceutical companies and key healthcare institutions, solidifying its role in leveraging AI for precision oncology and drug discovery. Investors maintain a bullish long-term outlook, emphasizing the company's foundational impact on healthcare technology.

Rydex Investments - Invesco CurrencyShares British Pound Sterling Trust

Invesco CurrencyShares British Pound Sterling Trust

FXB is trending as recent weaker UK inflation and economic data have solidified market expectations for aggressive Bank of England rate cuts. The investment community is actively debating the implications of this monetary policy divergence, which is weighing significantly on the British Pound's value and driving conversation around sterling's immediate outlook against other major currencies.

Rydex Investments - Invesco CurrencyShares Euro Trust

Invesco CurrencyShares Euro Trust

The Invesco CurrencyShares Euro Trust is actively trending as the Euro shows resilience against the U.S. Dollar, largely driven by market speculation around potential shifts in Federal Reserve policy and concerns over its independence. The community is focused on how these dynamics, alongside mixed Eurozone data and contrasting central bank outlooks, are influencing EUR/USD exchange rates.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is generating significant buzz through its $1 billion AI drug discovery partnership with NVIDIA and strategic acquisitions like Ventyx Biosciences, aimed at diversifying its pipeline. This comes as the company faces heightened scrutiny in the competitive GLP-1 market, with community discussion centered on Novo Nordisk's recent FDA approval of an oral weight-loss pill and its implications for LLY's market position and upcoming oral drug approval.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox (RBLX) is actively discussed as the company implements mandatory age verification for chat features, a move intended to address mounting regulatory scrutiny and child safety lawsuits but sparking community debate over its impact on user engagement. The stock is experiencing significant volatility amid conflicting analyst ratings, with some downgrades citing concerns about future bookings, while others see it as a long-term buy due to oversold conditions and strong user growth. This creates a push-and-pull as investors weigh the platform's evolving safety measures and market perception against its growth trajectory in the competitive gaming sector.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is generating significant buzz following promising Phase 1 clinical data for CTX310, demonstrating deep and durable lipid reductions without serious adverse events. This breakthrough, published in The New England Journal of Medicine, validates the company's in vivo gene-editing platform and excites the community about its potential as a "one-and-done" treatment for severe lipid disorders. Investors anticipate substantial market recognition for this development, alongside ongoing pipeline progress in a field gaining new regulatory support.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) is experiencing significant market attention following positive feedback from the FDA, which confirmed existing trial data is sufficient for a Biologics License Application for its drug sonelokimab in hidradenitis suppurativa, greatly de-risking its regulatory pathway. This development has fueled widespread speculation within the community about potential acquisition bids from major pharmaceutical players like Merck and Eli Lilly, with many investors anticipating a substantial revaluation and a potential short squeeze due to high interest from sellers. The discussion highlights the company's strong asset in the competitive immunology sector and its clearer path to market.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending amid significant short interest fueling massive short squeeze speculation, compounded by a recent positive update on its market share in Japan. The community is keenly focused on the J.P. Morgan Healthcare Conference for potential game-changing partnership announcements or a buyout. This backdrop, alongside mounting activist investor pressure, underscores an urgent demand for value creation from management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

3 Medical Supplies Stocks That Beat the Market Despite Macro Headwinds

Cardinal Health, McKesson, and Cencora are showing how scale, specialty focus, and execution can drive market-beating returns despite macro pressure.

Commonwealth Equity Services LLC Reduces Stake in Cencora, Inc. $COR

Commonwealth Equity Services LLC lowered its position in Cencora, Inc. (NYSE:COR - Free Report) by 7.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange...

Why Cencora (COR) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why You Should Retain Cencora Stock in Your Portfolio Now

Cencora's strength in U.S. Healthcare Solutions, along with rising specialty drug demand and biosimilar adoption, supports growth, though competitive pressures and international weakness remain headwinds.

Here's Why Cencora (COR) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cencora, Inc. $COR Stock Position Lowered by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC decreased its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 20.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and...

Robeco Institutional Asset Management B.V. Purchases 20,713 Shares of Cencora, Inc. $COR

Robeco Institutional Asset Management B.V. boosted its position in Cencora, Inc. (NYSE:COR - Free Report) by 11.6% during the third quarter, according to its most recent 13F filing with the SEC. The...

Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release

Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York...

McKesson Builds Earnings Momentum on Specialty and Automation

McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.

Bank of America Lowers Cencora (NYSE:COR) Price Target to $360.00

Bank of America dropped their price objective on Cencora from $380.00 to $360.00 and set a "neutral" rating on the stock in a research note on Monday...

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment is involved in the offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

Cencora Inc.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

COR
Cencora Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest COR News

CORCencora Inc.